HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (86) Citing Articles via Google Scholar Google Scholar Articles by Rifai, N. Articles by Ridker, P. M. Search for Related Content PubMed PubMed Citation Articles by Rifai, N. Articles by Ridker, P. M. Related Collections Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers

Proposed Cardiovascular Risk Assessment Algorithm Using High-Sensitivity C-Reactive Protein and Lipid Screening

¹ Department of Laboratory Medicine, Children’s Hospital,
² Center for Cardiovascular Disease Prevention, The Leducq Center for Molecular and Genetic Epidemiology of Cardiovascular Disorders,
³ Divisions of Cardiovascular Disease and Preventive Medicine, Brigham and Women’s Hospital, and, Departments of
⁴ Pathology and
⁵ Medicine, Harvard Medical School, Boston, MA 02115
^a Address correspondence to this author at: Children’s Hospital, Department of Laboratory Medicine, 300 Longwood Ave., Boston, MA 02115. Fax 617-713-4347; rifai@tch.harvard.edu.

	Introduction

 
Several prospective epidemiologic studies from the United States and Europe have demonstrated that high-sensitivity C-reactive protein (hs-CRP) is a predictor of future coronary events among apparently healthy men and women. For example, findings from the Multiple Risk Factors Intervention Trial demonstrated a correlation between hs-CRP and coronary heart disease mortality among male smokers followed over a 17-year period [relative risk (RR) = 2.8; 95% confidence interval (CI), 1.4–5.4] (1). A similar positive association between hs-CRP and future coronary events was noted in the Cardiovascular Health Study and Rural Health Promotion Project, which included elderly men and women with subclinical cardiovascular disease (2). A direct positive association between hs-CRP and future coronary events was also reported in apparently healthy men from the Physician’s Health Study (PHS); those in the highest quartile of hs-CRP had twice the risk of future stroke (RR = 1.9; 95% CI, 1.1–3.3), three times the risk of future myocardial infarction (RR = 2.9; 95% CI, 1.8–4.6), and four times the risk of future peripheral vascular disease (RR = 4.1; 95% CI, 1.2–6.0) (3)(4). Furthermore, both the MONICA-Augsburg cohort (5) and the Helsinki Heart Study (6) showed that compared with those with low hs-CRP, individuals with the highest hs-CRP concentrations were at approximately three times the risk of developing future coronary events. Finally, two reports from the Women’s Health Study (WHS) showed that hs-CRP is also a strong predictor of future cardiovascular events in women (RR = 4.4; 95% CI, 2.2–8.9) (7)(8). In fact, in that study, which directly compared several novel risk factors to standard lipid screening, hs-CRP was the single strongest predictor of . . . [Full Text of this Article]

	References

 

The following articles in journals at HighWire Press have cited this article:

				R. Kones The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 309 - 315. [Abstract] [PDF]

				M. Guardiola, R. Ferre, J. Salazar, C. Alonso-Villaverde, B. Coll, S. Parra, L. Masana, and J. Ribalta Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5-1131T->C Gene Variation Clin. Chem., October 1, 2006; 52(10): 1914 - 1919. [Abstract] [Full Text] [PDF]

				A. S. Jaffe, L. Babuin, and F. S. Apple Biomarkers in Acute Cardiac Disease: The Present and the Future J. Am. Coll. Cardiol., July 4, 2006; 48(1): 1 - 11. [Abstract] [Full Text] [PDF]

				A. Stefanska, G. Sypniewskay, and L. Senterkiewicz Inflammatory Markers and Cardiovascular Risk in Healthy Polish Women across the Menopausal Transition Clin. Chem., October 1, 2005; 51(10): 1893 - 1895. [Full Text] [PDF]

				G. L. Myers, N. Rifai, R. P. Tracy, W. L. Roberts, R. W. Alexander, L. M. Biasucci, J. D. Catravas, T. G. Cole, G. R. Cooper, B. V. Khan, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Laboratory Science Discussion Group Circulation, December 21, 2004; 110(25): e545 - e549. [Full Text] [PDF]

				R. Rej Clinical Chemistry through Clinical Chemistry: A Journal Timeline Clin. Chem., December 1, 2004; 50(12): 2415 - 2458. [Abstract] [Full Text] [PDF]

				S. S. Levinson, J. J. Miller, and R. J. Elin Poor Predictive Value of High-Sensitivity C-Reactive Protein Indicates Need for Reassessment Clin. Chem., October 1, 2004; 50(10): 1733 - 1735. [Full Text] [PDF]

				U. A. Ajani, E. S. Ford, and A. H. Mokdad Prevalence of High C-Reactive Protein in Persons with Serum Lipid Concentrations within Recommended Values Clin. Chem., September 1, 2004; 50(9): 1618 - 1622. [Abstract] [Full Text] [PDF]

				J. H. Ix, M. G. Shlipak, H. H. Liu, N. B. Schiller, and M. A. Whooley Association between Renal Insufficiency and Inducible Ischemia in Patients with Coronary Artery Disease: The Heart and Soul Study J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3233 - 3238. [Abstract] [Full Text] [PDF]

				N. Khuseyinova, A. Imhof, G. Trischler, D. Rothenbacher, W. L. Hutchinson, M. B. Pepys, and W. Koenig Determination of C-Reactive Protein: Comparison of Three High-Sensitivity Immunoassays Clin. Chem., October 1, 2003; 49(10): 1691 - 1695. [Full Text] [PDF]

				T. B. Ledue and N. Rifai Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment Clin. Chem., August 1, 2003; 49(8): 1258 - 1271. [Abstract] [Full Text] [PDF]

				E. S. Ford, W. H. Giles, G. L. Myers, N. Rifai, P. M. Ridker, and D. M. Mannino C-reactive Protein Concentration Distribution among US Children and Young Adults: Findings from the National Health and Nutrition Examination Survey, 1999-2000 Clin. Chem., August 1, 2003; 49(8): 1353 - 1357. [Abstract] [Full Text] [PDF]

				C.J. Malkin, P.J. Pugh, T.H. Jones, and K.S. Channer Testosterone for secondary prevention in men with ischaemic heart disease? QJM, July 1, 2003; 96(7): 521 - 529. [Full Text] [PDF]

				I. M. van der Meer, M. P. M. de Maat, A. J. Kiliaan, D. A. M. van der Kuip, A. Hofman, and J. C. M. Witteman The Value of C-Reactive Protein in Cardiovascular Risk Prediction: The Rotterdam Study Arch Intern Med, June 9, 2003; 163(11): 1323 - 1328. [Abstract] [Full Text] [PDF]

				Y.-C. Tsen, G.-Y. Kao, C.-L. Chang, F.-Y. Lai, C.-H. Huang, S. Ouyang, M.-H. Yu, C.-P. Wang, and Y-N. Chiou Evaluation and Validation of a Duck IgY Antibody-based Immunoassay for High-Sensitivity C-reactive Protein: Avian Antibody Application in Clinical Diagnostics Clin. Chem., May 1, 2003; 49(5): 810 - 813. [Full Text] [PDF]

				C.-H. Wang, S.-H. Li, R. D. Weisel, P. W.M. Fedak, A. S. Dumont, P. Szmitko, R.-K. Li, D. A.G. Mickle, and S. Verma C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle Circulation, April 8, 2003; 107(13): 1783 - 1790. [Abstract] [Full Text] [PDF]

				M. M. Kimberly, H. W. Vesper, S. P. Caudill, G. R. Cooper, N. Rifai, F. Dati, and G. L. Myers Standardization of Immunoassays for Measurement of High-Sensitivity C-reactive Protein. Phase I: Evaluation of Secondary Reference Materials Clin. Chem., April 1, 2003; 49(4): 611 - 616. [Abstract] [Full Text] [PDF]

				N. Rifai and P. M. Ridker Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States: Implication for Clinical Interpretation Clin. Chem., April 1, 2003; 49(4): 666 - 669. [Full Text] [PDF]

				A. Imhof, M. Frohlich, H. Loewel, N. Helbecque, M. Woodward, P. Amouyel, G. D.O. Lowe, and W. Koenig Distributions of C-reactive Protein Measured by High-Sensitivity Assays in Apparently Healthy Men and Women from Different Populations in Europe Clin. Chem., April 1, 2003; 49(4): 669 - 672. [Full Text] [PDF]

				E. S. Ford, W. H. Giles, G. L. Myers, and D. M. Mannino Population Distribution of High-Sensitivity C-reactive Protein among US Men: Findings from National Health and Nutrition Examination Survey 1999-2000 Clin. Chem., April 1, 2003; 49(4): 686 - 690. [Full Text] [PDF]

				T. C. Vukovich, S. Mustafa, H. Rumpold, and O. Wagner Evaluation of a Turbidimetric Denka Seiken C-Reactive Protein Assay for Cardiovascular Risk Estimation and Conventional Inflammation Diagnosis Clin. Chem., March 1, 2003; 49(3): 511 - 512. [Full Text] [PDF]

				M. S. Beattie, M. G. Shlipak, H. Liu, W. S. Browner, N. B. Schiller, and M. A. Whooley C-Reactive Protein and Ischemia in Users and Nonusers of {beta}-Blockers and Statins: Data From the Heart and Soul Study Circulation, January 21, 2003; 107(2): 245 - 250. [Abstract] [Full Text] [PDF]

				N. Sattar, C. G Perry, and J. R Petrie Type 2 diabetes as an inflammatory disorder The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 36 - 41. [Abstract] [PDF]

				I. M. van der Meer, M. P.M. de Maat, A. E. Hak, A. J. Kiliaan, A. I. del Sol, D. A.M. van der Kuip, R. L.G. Nijhuis, A. Hofman, and J. C.M. Witteman C-Reactive Protein Predicts Progression of Atherosclerosis Measured at Various Sites in the Arterial Tree: The Rotterdam Study Stroke, December 1, 2002; 33(12): 2750 - 2755. [Abstract] [Full Text] [PDF]

				J. Middleton Effect of Analytical Error on the Assessment of Cardiac Risk by the High-Sensitivity C-Reactive Protein and Lipid Screening Model Clin. Chem., November 1, 2002; 48(11): 1955 - 1962. [Abstract] [Full Text] [PDF]

				S. Verma, C.-H. Wang, S.-H. Li, A. S. Dumont, P. W.M. Fedak, M. V. Badiwala, B. Dhillon, R. D. Weisel, R.-K. Li, D. A.G. Mickle, et al. A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis Circulation, August 20, 2002; 106(8): 913 - 919. [Abstract] [Full Text] [PDF]

				R.J. de Winter, G.S. Heyde, K.T. Koch, J. Fischer, J.P. van Straalen, M. Bax, C.E. Schotborgh, K.J. Mulder, G.T. Sanders, J.J. Piek, et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty Eur. Heart J., June 2, 2002; 23(12): 960 - 966. [Abstract] [Full Text] [PDF]

				I. Kushner and A. R. Sehgal Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk? Arch Intern Med, April 22, 2002; 162(8): 867 - 869. [Abstract] [Full Text] [PDF]

				S. S. Levinson High Density- and Beta-Lipoprotein Screening for Risk of Coronary Artery Disease in the Context of New Findings on Reverse Cholesterol Transport Ann. Clin. Lab. Sci., April 1, 2002; 32(2): 123 - 136. [Abstract] [Full Text] [PDF]

				S. S. Levinson and R. J. Elin What Is C-Reactive Protein Telling Us About Coronary Artery Disease? Arch Intern Med, February 25, 2002; 162(4): 389 - 392. [Full Text] [PDF]

				P. Tarkkinen, T. Palenius, and T. Lovgren Ultrarapid, Ultrasensitive One-Step Kinetic Immunoassay for C-Reactive Protein (CRP) in Whole Blood Samples: Measurement of the Entire CRP Concentration Range with a Single Sample Dilution Clin. Chem., February 1, 2002; 48(2): 269 - 277. [Abstract] [Full Text] [PDF]

				A. Hamwi, T. Vukovich, O. Wagner, H. Rumpold, R. Spies, M. Stich, and C. Langecker Evaluation of Turbidimetric High-Sensitivity C-Reactive Protein Assays for Cardiovascular Risk Estimation Clin. Chem., November 1, 2001; 47(11): 2044 - 2046. [Full Text] [PDF]

				R. P. Tracy Is Visceral Adiposity the "Enemy Within"? Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 881 - 883. [Full Text] [PDF]

				U.-H. Stenman Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable? Clin. Chem., May 1, 2001; 47(5): 815 - 820. [Full Text] [PDF]

				N. Rifai and P. M. Ridker High-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease Clin. Chem., March 1, 2001; 47(3): 403 - 411. [Abstract] [Full Text] [PDF]

				W. L. Roberts, L. Moulton, T. C. Law, G. Farrow, M. Cooper-Anderson, J. Savory, and N. Rifai Evaluation of Nine Automated High-Sensitivity C-Reactive Protein Methods: Implications for Clinical and Epidemiological Applications. Part 2 Clin. Chem., March 1, 2001; 47(3): 418 - 425. [Abstract] [Full Text] [PDF]

				H. K. Meier-Ewert, P. M. Ridker, N. Rifai, N. Price, D. F. Dinges, and J. M. Mullington Absence of Diurnal Variation of C-Reactive Protein Concentrations in Healthy Human Subjects Clin. Chem., March 1, 2001; 47(3): 426 - 430. [Abstract] [Full Text] [PDF]

				W. Koenig C-Reactive Protein and Cardiovascular Risk: Has the Time Come for Screening the General Population? Clin. Chem., January 1, 2001; 47(1): 9 - 10. [Full Text] [PDF]

				S. Verma, S.-H. Li, M. V. Badiwala, R. D. Weisel, P. W.M. Fedak, R.-K. Li, B. Dhillon, and D. A.G. Mickle Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein Circulation, April 23, 2002; 105(16): 1890 - 1896. [Abstract] [Full Text] [PDF]